Canton Strategic Holdings Reports $47.3 Million Net Loss and Launches Digital Asset Strategy

Canton Strategic Holdings, Inc., formerly known as Tharimmune, Inc., reported significant financial developments in its latest 10-Q filing for the first quarter of 2026. The company recorded a net loss of $47.3 million, or $0.23 per share, compared to a net loss of $2.5 million, or $0.99 per share, in the same period of the previous year. Total operating expenses surged to $36.9 million, a substantial increase from $2.5 million in the prior year, primarily driven by a rise in general and administrative expenses, which reached $36.6 million, up from $2 million. The increase in expenses reflects the company's strategic shift towards a digital asset treasury strategy and the associated operational costs.

Canton Strategic's total assets increased to $584.7 million as of March 31, 2026, compared to $519.1 million at the end of 2025. This growth was largely attributed to a rise in cash reserves, which climbed to $41.5 million from $17 million, and an increase in digital assets, which rose to $541.6 million from $501.8 million. The company's liabilities decreased to $114.9 million from $121.2 million, primarily due to a reduction in current liabilities, which fell to $1.1 million from $3.3 million. The company's stockholders' equity also saw a significant increase, reaching $469.8 million, up from $397.9 million.

Strategically, the company has made notable changes, including the launch of a digital asset treasury strategy aimed at leveraging Canton Coin (CC) to support blockchain adoption and financial market digitization. This initiative has led to a rebranding from Tharimmune, Inc. to Canton Strategic Holdings, Inc. as of February 18, 2026. The company is now focused on operating as a Super Validator on the Canton Network, which is expected to enhance its digital asset holdings and operational capabilities.

Operationally, the company has made strides in its clinical-stage biotechnology business through its subsidiary, Gravitas Life Sciences, Inc. Gravitas is advancing its lead candidate, GV104, which is being developed for the prophylaxis of respiratory and nervous system depression in military personnel. The FDA has indicated that no additional clinical trials are necessary for the submission of a New Drug Application (NDA) for GV104, which positions the company favorably for future growth in the biotechnology sector.

Looking ahead, Canton Strategic Holdings has expressed optimism regarding its digital asset strategy and the potential for growth in its biotechnology segment. However, the company acknowledges the inherent risks and uncertainties associated with its forward-looking statements, including market conditions and the volatility of digital assets. The management remains focused on executing its strategic initiatives while navigating the challenges of the evolving market landscape.